EMA And National Agency Heads Join Forces On Medicines Availability and Big Data

 
• By Maureen Kenny
  
Generate a summary of this article
Listen to this article
Beta

The European Medicines Agency and the EU Heads of Medicines Agencies network are working together on a broad range of subjects, from big data to the availability of medicines… and of course, Brexit.

The European Medicines Agency and national agency heads are working together on the availability of medicines and big data in medicines evaluation, the EMA is extending a multinational approach to drug assessment that is reducing the agency’s reliance on UK experts in preparation for Brexit, and new guidance is planned by the EMA on data integrity. These are just some of the many regulatory developments that EMA deputy executive director Noel Wathion covered in his presentation at the Annual European Medicines Agency Review of the Year and Outlook for 2017 conference, which took place recently in London.

The Pink Sheet will report in more detail on some of these topics over the coming weeks. In the meantime,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Distribution/Supply Chain

Akash test for clone

 
• By akash

Test article to check the clone issue

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 
• By Sarah Karlin-Smith

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.

French Fine 11 Firms For Failure To Meet Stock Obligations

 
• By Ian Schofield

A total of 748 key medicines are now affected by the four-month stock requirement, compared with 422 in 2021.

Responsible Antimicrobial Manufacturing A Must For UK’s Subscription Model Applicants

 
• By Eliza Slawther

The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.

More from Compliance

HTA Regulation: EU Publishes Guidance On Validity Of Clinical Studies For Joint Clinical Assessments

 
• By Francesca Bruce

Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By Vibha Sharma

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.

Draft US FDA Innovative Manufacturing Strategy Takes On Global Inconsistency

 
• By Bridget Silverman

The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.